Marshall Wace North America’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Marshall Wace North America’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$276K	Sell	1,558 -9,037	-85%	-$1.45M	﹤0.01%	1268
2021 Q2	$1.71M	Sell	10,595 -231,254	-96%	-$37.1M	0.01%	855
2021 Q1	$41.4M	Sell	241,849 -179,983	-43%	-$35.6M	0.17%	141
2020 Q4	$92.7M	Buy	421,832 +405,650	+2,507%	+$87.7M	0.42%	48
2020 Q3	$2.69M	Buy	+16,182	New	+$2.21M	0.02%	510
2020 Q2	–	Sell	-33,529	Closed	-$2.58M	–	1560
2020 Q1	$2.58M	Buy	+33,529	New	+$3.01M	0.02%	439
2019 Q3	–	Sell	-19,708	Closed	-$2.03M	–	1606
2019 Q2	$2.03M	Buy	+19,708	New	+$1.53M	0.01%	563
2018 Q4	–	Sell	-323,793	Closed	-$15.3M	–	1685
2018 Q3	$15.3M	Sell	323,793 -480,983	-60%	-$26.8M	0.1%	164
2018 Q2	$39.7M	Buy	804,776 +495,017	+160%	+$18.7M	0.22%	110
2018 Q1	$9.51M	Buy	309,759 +297,205	+2,367%	+$8.25M	0.05%	409
2017 Q4	$229K	Sell	12,554 -124,398	-91%	-$1.93M	﹤0.01%	1268
2017 Q3	$1.64M	Buy	+136,952	New	+$792K	0.01%	847

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Marshall Wace North America's MRTX Position: Q3 2021 in Review

Marshall Wace North America reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 85% in Q3 2021, selling an estimated $1.45M and leaving 1,558 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Marshall Wace North America first reported a position in MRTX in Q3 2017 and has held it in 12 quarters since. The position peaked at $92.7M in Q4 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

Marshall Wace North America held 1,558 shares of Mirati Therapeutics, Inc. Common Stock worth $276K as of Q3 2021.
Marshall Wace North America sold 9,037 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.45M.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1268 holding.
Marshall Wace North America first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2017 and has held it in 12 quarters since.
Marshall Wace North America's Mirati Therapeutics, Inc. Common Stock position peaked at $92.7M in Q4 2020.
238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.